Abstract
The new antiviral drugs famiciclovir and valacyclovir are effective for the treatment of recurrent gential herpes and herpes zostar and may be given less frequently than acyclovir. Asymptomatic shedding of herpes simplex virus type 2 may be reduced by administration of daily acyclovir. Recombinant genetic techniques that allow viral protein production in vitro are being used in herpes simplex and papilloma virus vaccine development. Administatrtion of a live attenuated varicella-zoster virus vaccine provides long-lasting measures of cellular immunity in the elderly.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
